1. Basic Information
Disease Protected Against
Meningococcal disease, caused by Neisseria meningitidis, presents as meningitis and/or septicemia. It is among the most rapidly progressive bacterial infections — a previously healthy person can die within 24 hours. Case-fatality is ~10–15% even with appropriate antibiotics; 11–19% of survivors have permanent sequelae (limb loss, neurological damage, hearing loss). Six serogroups (A, B, C, W, X, Y) cause most invasive disease. In the U.S., serogroups B and C predominate in adolescents; B predominates in infants. The U.S. incidence is low (~0.1–0.2 per 100,000; ~300–400 cases/year) but outbreaks occur in college settings.
CDC Schedule (U.S., 2025)
| Vaccine | Age | Schedule |
|---|---|---|
| MenACWY (dose 1) | 11–12 years | Routine adolescent dose |
| MenACWY (dose 2) | 16 years | Booster; important for protection during highest-risk college years |
| MenACWY (high-risk) | As early as 2 months (Menveo/MenQuadfi) or 9 months (Menactra) | Complement deficiency, asplenia, HIV, outbreak settings, travel |
| MenB (shared clinical decision-making) | 16–23 years (preferred 16–18) | Bexsero: 2-dose series; Trumenba: 2-dose or 3-dose depending on risk |
Source: CDC ACIP, 2025 schedule. MenB is not universally recommended; shared clinical decision-making acknowledges the low absolute risk and high cost of the vaccine.
2. Pre-Licensure Clinical Trial Data
MenACWY vaccines were licensed based on immunogenicity (serum bactericidal antibody) rather than clinical efficacy, because meningococcal disease is too rare to power an efficacy trial. Menactra (Sanofi) was first licensed in 2005; Menveo (GSK) in 2010; MenQuadfi (Sanofi) in 2020. MenB vaccines (Bexsero/GSK 2015, Trumenba/Pfizer 2014) were licensed based on immunogenicity using a novel approach (hSBA assay against diverse MenB strains) — the first vaccines licensed under the FDA accelerated approval pathway using immunogenicity endpoints.
| Metric | MenACWY Data | MenB Data |
|---|---|---|
| Pre-licensure safety database | ~10,000+ per product | ~8,000 (Bexsero), ~5,000 (Trumenba) |
| Efficacy basis | Immunobridging (SBA titers); effectiveness confirmed post-licensure | Immunogenicity (hSBA); effectiveness data limited but emerging |
| Seroresponse | >85–95% for all 4 serogroups | 67–94% against diverse MenB test strains |
Most Common Adverse Reactions
| Reaction | MenACWY (Approx.) | MenB (Approx.) |
|---|---|---|
| Injection site pain | ~40–60% | ~85–95% (MenB is substantially more reactogenic) |
| Injection site swelling/erythema | ~15–25% | ~30–50% |
| Fever | ~3–8% | ~10–20% (higher when co-administered with other adolescent vaccines) |
| Headache | ~20–30% | ~30–45% |
| Fatigue/malaise | ~15–25% | ~30–50% |
| Myalgia/arthralgia | ~10–20% | ~30–50% |
MenB vaccines are notably more reactogenic than MenACWY, with high rates of local and systemic reactions. This reactogenicity contributes to the shared clinical decision-making framework for MenB.
3. Post-Licensure Safety Data
VSD Findings
- Guillain-Barré Syndrome (GBS) — Menactra: A VSD rapid cycle analysis in 2005–2006 identified a possible GBS signal following Menactra (MCV4-D). 17 GBS cases were reported to VAERS within 6 weeks of vaccination. Subsequent VSD and larger analyses estimated ~0.5–1.5 excess GBS cases per million doses, but results were not consistent across all studies. ACIP did not change the recommendation. Menveo and MenQuadfi have not shown a GBS signal.
- Syncope: As with all adolescent vaccines, syncope is observed. 15-minute observation recommended.
- No other consistent safety signals identified for MenACWY or MenB in VSD. MenB vaccines have been associated with higher rates of fever-related medical visits than MenACWY due to their higher reactogenicity profile.
- Bell's palsy: A very small numerical imbalance was observed in Bexsero pre-licensure trials (4 cases vs. 0 placebo). No signal confirmed post-licensure.
⚠ Critical Caveat
VAERS data represent unverified reports. A report to VAERS does not mean the vaccine caused the event.
4. Documented Adverse Events
▶ Strong Evidence
- Injection site reactions: Common; MenB (85–95% pain) >> MenACWY (40–60%). Strong
- Systemic reactions: Fever, headache, fatigue, myalgia. More common with MenB. Strong
- Syncope: Adolescent vasovagal response. Strong
- Anaphylaxis: ~1 per million doses. Strong
▶ Moderate or Preliminary Evidence
- GBS (Menactra-specific): Possible small increased risk (~0.5–1.5 per million doses). Signal not consistently replicated; not observed with Menveo or MenQuadfi. Moderate
5. Disease Prevention Benefits
| Metric | Pre-Vaccine Era | Post-Vaccine Era |
|---|---|---|
| Meningococcal incidence (U.S., all ages) | ~1.0–1.5 per 100,000 (1990s) | ~0.1–0.2 per 100,000; >90% reduction in vaccine serogroups (C, W, Y); serogroup B now predominates |
| Adolescent meningococcal disease | ~15% of cases age 11–24; highest CFR | >80% reduction in ACWY disease in vaccinated age groups |
| College outbreaks | Multiple outbreaks in the 1990s–2000s | Rare (primarily MenB); MenACWY college entry requirements have been effective |
Source: CDC MMWR; CDC Pink Book. MenB disease has not declined as dramatically because MenB vaccine uptake is low (shared clinical decision-making) and serogroup B vaccine coverage is not yet population-level.
6. Evidence Summary
MenACWY vaccines have a well-established safety record and demonstrated real-world effectiveness. The Menactra GBS signal remains an area of ongoing monitoring but has not changed vaccine policy. MenB vaccines are distinguished by their high reactogenicity profile, limited clinical efficacy data (licensed on immunogenicity), and the shared clinical decision-making framework — reflecting a different risk-benefit calculus from universally recommended vaccines. The low absolute incidence of meningococcal disease in the U.S. limits the statistical power of post-licensure safety studies for very rare adverse events.
7. Key References
- IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012.
- CDC. Pink Book — Meningococcal chapter. cdc.gov/pinkbook
- Velentgas P, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012;21(12):1350–1358.
- CDC. VSD. cdc.gov/vaccine-safety/about/vsd.html
- CDC/FDA. VAERS. vaers.hhs.gov